Why are you doubling down and what is the money being used for. Well, first of all, thanks so much for for having us here. It's a really exciting time for the company we're coming out of this year with a series of research breakthroughs where we've now shown that we can use A.I. to design molecules that we never even thought was going to be possible. So we're really using this money to double down on that research agenda.The models show no signs of of slowing down, and then also really growing the team and ...

Hear from Nicky Vallelly on what it’s really like to work at @IsomorphicLabs and the unique, interdisciplinary culture that powers our mission to solve all disease.We're looking for a wide variety of people, from machine learning experts to drug discovery scientists.Watch Nicky’s video and head to the comments for a link to our current roles. ...

We were delighted to welcome HRH Prince Daniel of Sweden, Marcus Wallenberg, and a group of future business leaders to the @IsomorphicLabs head office in London last month, as part of a visit from Prince Daniel’s Fellowship.During the visit, @maxjaderberg and @_rebecca_paul shared how Iso is leading a new era of drug discovery where frontier AI can unlock deeper scientific insights, faster breakthroughs and life-changing medicines. ...

Core Concept - The term "meme stock" refers to publicly traded companies that experience rapid increases in market value due to trading activity on online platforms, often driven by community interest [1] Company Overview - Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech company focused on drug discovery utilizing artificial intelligence [2] - The company has been suggested to be a meme stock by Jim Cramer, a notable figure in the investment community [5] Stock Performance Analysis - Recursion Pharmaceuticals has been on a downward trend for most of the year, with volatility typical for clinical-stage biotechs [4] - There is limited interest in Recursion on social media, which does not support the classification as a meme stock [4] - Following Cramer's suggestion on October 22, the stock has not consistently increased, underperforming compared to broader equities [6] Investment Viability - A characteristic of meme stocks is that their fundamentals do not correlate with stock performance; however, Recursion's financial performance does not align with the meme stock narrative [7] - Despite being labeled as a meme stock, Recursion Pharmaceuticals may not be a viable investment option [8]

Core Insights - N2OFF, Inc. has completed the acquisition of MitoCareX Bio Ltd., focusing on the precision oncology market and leveraging MitoCareX's proprietary MITOLINE algorithm for drug discovery [1][2][3] Company Overview - MitoCareX Bio Ltd. is a biotechnology company utilizing MITOLINE, an algorithm for 3D modeling of mitochondrial transport proteins, to develop therapies for difficult-to-treat cancers [2][4] - The company targets mitochondrial SLC25 transport proteins, which are crucial in the metabolic reprogramming of aggressive cancers like lung and pancreatic cancer, with a projected global therapeutic market exceeding $50 billion by 2026 [3][4] Strategic Direction - MitoCareX aims to optimize hit-to-lead medicinal chemistry and pharmacokinetic profiling in 2026, with the goal of nominating a preclinical development candidate [5] - The company is exploring strategic collaborations and licensing agreements to expand MITOLINE's applications, creating non-dilutive revenue opportunities [6][7] Long-Term Vision - The long-term strategy includes preparing for IND-enabling studies to transition MitoCareX toward clinical readiness while establishing MITOLINE as a scalable discovery engine [7][8] - MitoCareX's approach combines mitochondrial biology, computational modeling, and precision oncology, positioning it uniquely in the biotech sector [8][9] Innovation and Value Creation - The MITOLINE algorithm enables high-throughput in silico screening of small molecules, accelerating the drug discovery process [4][10] - The company aims to build a repeatable, data-driven discovery platform that transforms mitochondrial biology into sustained innovation and value creation [10][11]

Hear more about our work unlocking new possibilities for drug discovery by joining our Chief Scientific Officer, @MilesCcc, in Boston at the AI-Driven Drug Discovery Summit 2025 at 12:45 EST on 19 November.In his presentation, Miles will explore AI-driven protein structure prediction, sharing insights from our work at Isomorphic Labs and what it means for the discovery of new medicines.Find out more here: https://t.co/SYwbF4b8p1 ...

Company Activities - Isomorphic Labs 总裁 Colin Murdoch 将在伦敦金融时报人工智能峰会上发表主题演讲 [1] - Colin 将分享 Isomorphic Labs 如何利用人工智能重塑药物发现，以及在解决所有疾病方面的进展 [1] Event Details - 峰会时间：11 月 5 日星期三 14:50 GMT（格林威治标准时间） [1]

During @endpts News AI Day, @maxjaderberg and @MilesCcc talked about how building individual models for specific targets will limit forward progress, and how @IsomorphicLabs is generating foundational models that generalise across many.They also explored other topics shaping the future of AI-driven drug discovery, including the necessity of creating datasets specifically for the models that will consume them.Watch here:https://t.co/gWrLYEhXDZ ...

Core Insights - The article discusses the introduction of BoltzGen, a new model developed by MIT and several institutions to address the limitations of traditional protein design methods, which rely heavily on physical calculations and have high computational costs [1][2][3] Group 1: Model Overview - BoltzGen utilizes a unified all-atom generative model that replaces traditional discrete residue labels with geometric continuous representations, allowing for joint training of protein folding and complex design [2][3] - The model incorporates a flexible design specification language that enables controllable generation across different molecular types, enhancing design efficiency and interpretability [1][3] Group 2: Research Highlights - The model has demonstrated a 66% success rate in achieving nanomolar affinity for designed nanobodies and protein complexes, showcasing its ability to optimize folding and binding performance simultaneously [2][12] - BoltzGen's architecture integrates a trunk network for token representation and a diffusion module for generating three-dimensional structures, allowing for effective modeling of atomic relationships [10][11] Group 3: Experimental Validation - In experiments involving 26 targets, BoltzGen maintained a high success rate, achieving nanomolar affinity in 66% of cases for previously unseen complex targets [12][25] - The model has shown versatility in designing peptides that bind to various structures, including those related to acute myeloid leukemia and specific enzymes, with binding affinities ranging from nanomolar to micromolar levels [15][17][19] Group 4: Data Utilization - The training of BoltzGen involved a multi-modal dataset sourced from high-quality experimental structures, AlphaFold predictions, and generated complex structures, enhancing the model's generalization capabilities [7][9] - The research team ensured diversity in the training data by excluding over-sampled datasets, maintaining a broad generation space [9]

Event Details - Isomorphic Labs 的两位高管 Max Jaderberg (Chief AI Officer) 和 MilesCcc (Chief Scientific Officer) 将于 2026 年 10 月 14 日参加 Endpoints AI Day 的炉边谈话 [1] - 炉边谈话时间为美国东部时间上午 11:00 至 11:40，共计 40 分钟 [1] Focus of Discussion - Isomorphic Labs 将深入探讨 AI 如何与药物发现相结合 [1] - Isomorphic Labs 的药物设计引擎使其能够在多个治疗领域和药物模式中运营 [1]